Study the impact of Adriamycin therapy in breast cancer patients on strain and strain rate parameters by echocardiography.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014060112924N2

Enrollment

Registered

2014-09-02

Start date

2012-04-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Malignant neoplasm of breast

Interventions

adriamycin 230mg/m2 in 6 cycles, 3 weeks interval.

Treatment - Drugs

adriamycin 230mg/m2 in 6 cycles, 3 weeks interval

Eligibility

Sex/Gender

Female

Age

No minimum to 65 Years

Inclusion criteria

Inclusion criteria: inclusion: breast cancer patients who are candidate for chemotherapy with adriamycin. exclusion: documented heart disease; history of radiation or chemotherapy for cancer; metastatic disease; atrial fibrillation; BMI more than 30; creatinin more than 2.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Strain rate. Timepoint: before starting, 10 days after 3rd cycle and 10 days after 6th cycle of chemotherapy. Method of measurement: echocardiography.	—

Secondary

Measure	Time frame
Ejection fraction. Timepoint: before starting, 10 days after 3rd cycle and 10 days after 6th cycle of chemotherapy. Method of measurement: echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Tashakori Behesht

Cardiovascular Research Center, Mashhad University of Medical Sceinces

tashakoriba851@mums.ac.ir+98 51 1840 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026